Presentation and pathophysiology of neuro-COVID

Josef Finsterer, Fulvio Alexandre Scorza, Carla Alexandra Scorza

Article Type

Letter-to-the-Editor

Published

Letter to the Editor commenting on Orsucci D, Caldarazzo Ienco E, Nocita G, Napolitano A, Vista M. Neurological features of COVID-19 and their treatment: a review. Drugs Context. 2020;9:2020-5-1.

Read more

Oscillococcinum® for upper respiratory tract infections and exacerbations in COPD: an observational, prospective study (OXITUNIS)

Hichem Aouina, Anis Bamri, Aurélien Vesin, Karine Danno, Eléonore Aubry, Cécile Faure, Naoual Boujedaini

Article Type

Original Research

Published

This article discussese the effectiveness of Oscillococcinum® in the protection from upper respiratory tract infections in patients with chronic obstructive pulmonary disease who had been vaccinated against influenza infection over the 2018–2019 winter season.

Read more

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide

Sarah M Michienzi, Mikayla Johnson, Thomas D Chiampas, Eric Wenzler, Rodrigo M Burgos, Renata O Smith, Melissa E Badowski

Article Type

Original Research

Published

The goal of this retrospective analysis is to assess changes in virological suppression, immunological status, renal function, weight and body mass index (BMI) amongst people living with HIV who switched from a tenofovir disoproxil fumarate-based to a tenofovir alafenamide-based regimen.

Read more

Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study

Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, Yulia S Karpova, Anton Tikhonov, Nadezhda F Khomyakova, Tim Hardman, Jean-François Rossi

Article Type

Corrigendum

Published

The authors wish to make the following corrections to their article: Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs in Context 2021; 10: 2021-11-1. DOI: 10.7573/dic.2020-11-1

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.